Overview and Scope
Nuclear medicine uses radioactive substances inside the body to diagnose illnesses or to target and remove diseased or damaged organs and tissue (for treatment). Nuclear medicine includes the use of radioactive drugs for research, therapeutic, and diagnostic purposes. Radioactive tracers are used in diagnostic nuclear medicine to visualize and/or measure the overall or local function of an organ.
Sizing and Forecast
The nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $6.57 billion in 2023 to $7.34 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to advancements in medical imaging, increasing prevalence of chronic diseases, aging population trends, clinical applications in oncology, diagnostic accuracy and precision.
The nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $11.31 billion in 2028 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to expanding applications in neurology, integration with other imaging modalities, precision medicine approaches, rising demand for theranostics, global efforts in disease eradication. Major trends in the forecast period include shift towards small-scale, decentralized radiopharmacy, application of nuclear medicine in neurology, radiomics and quantitative imaging analysis, collaborations for research and development, emphasis on radiation safety and dosimetry.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/nuclear-medicine-diagnostics-global-market-report
Segmentation & Regional Insights
The nuclear medicine diagnostics market covered in this report is segmented –
1) By Type: SPECT Radiopharmaceuticals, PET Radiopharmaceuticals
2) By Application: Cardiology, Thyroid, Neurology, Oncology, Other Applications
3) By End-User: Hospitals And Diagnostic Centers, Research Institutes
North America was the largest region in the nuclear medicine diagnostics market in 2023. The regions covered in the nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9415&type=smp
Major Driver Impacting Market Growth
The increasing demand for nuclear medicine diagnostics is expected to propel the growth of the nuclear medicine diagnostics market going forward. Nuclear medicine uses radioactive substances inside the body to diagnose illnesses or to target and remove diseased or damaged organs and tissue (for treatment). The diagnostic uses of nuclear medicine are primarily in radiation and other life-taking treatments. The demand for nuclear medicine diagnostics is increasing due to benefits such as accurate results and better treatment decision making. For instance, in April 2022, according to a report published on nuclear medicine diagnostics by the World Nuclear Association, a UK-based international organization that promotes nuclear power, the annual number of nuclear medicine treatments exceeds 40 million, and the need for radioisotopes is rising at a rate of up to 5% every year. Also, 90% of the procedures involving radioisotopes in medicine take place in more than 10,000 hospitals worldwide. Hence, increasing demand for nuclear medicine diagnostics is expected to propel the growth of the nuclear medicine diagnostics market.
Key Industry Players
Major companies operating in the nuclear medicine diagnostics market report are Siemens AG, Bayer Aktiengesellschaft, Novartis AG, GE Healthcare Technologies Inc., Perkin Elmer Inc., Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Cardinal Health Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited, Actinium Pharmaceuticals Inc., Jubilant DraxImage Inc., PharmaLogic Holdings Corp, Institute of Isotopes Co Ltd., Global Medical Solutions LLC, Theragnostics Ltd., Sirona Complete Care, Nordic Nanovector ASA, Eczacıbaşı-Monrol Nuclear Products Co
The nuclear medicine diagnostics market report table of contents includes:
1. Executive Summary
2. Nuclear Medicine Diagnostics Market Characteristics
3. Nuclear Medicine Diagnostics Market Trends And Strategies
4. Nuclear Medicine Diagnostics Market – Macro Economic Scenario
5. Global Nuclear Medicine Diagnostics Market Size and Growth
………………………………
32. Global Nuclear Medicine Diagnostics Market Competitive Benchmarking
33. Global Nuclear Medicine Diagnostics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Nuclear Medicine Diagnostics Market
35. Nuclear Medicine Diagnostics Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
